Tillman Pearce

1.5k total citations · 1 hit paper
35 papers, 789 citations indexed

About

Tillman Pearce is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Tillman Pearce has authored 35 papers receiving a total of 789 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Tillman Pearce's work include Lung Cancer Treatments and Mutations (7 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Cancer Research and Treatments (5 papers). Tillman Pearce is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Cancer Research and Treatments (5 papers). Tillman Pearce collaborates with scholars based in United States, Australia and New Zealand. Tillman Pearce's co-authors include S. Mawdsley, Rob Glynne‐Jones, Marc Buyse, Apostolia M. Tsimberidou, Daniël W. Hommes, Abhijit Chakraborty, Elena Fountzilas, Mehmet A. Baysal, L Simón and Paul Rutgeerts and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer Research.

In The Last Decade

Tillman Pearce

33 papers receiving 770 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Convergence of evolving artificial intelligence and machine learning techniques in precision oncology

2025 52 citations Elena Fountzilas, Tillman Pearce et al. npj Digital Medicine profile →

Peers

Countries citing papers authored by Tillman Pearce

Since Specialization

Citations

This map shows the geographic impact of Tillman Pearce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tillman Pearce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tillman Pearce more than expected).

Fields of papers citing papers by Tillman Pearce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tillman Pearce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tillman Pearce. The network helps show where Tillman Pearce may publish in the future.

Co-authorship network of co-authors of Tillman Pearce

This figure shows the co-authorship network connecting the top 25 collaborators of Tillman Pearce. A scholar is included among the top collaborators of Tillman Pearce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tillman Pearce. Tillman Pearce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Convergence of evolving artificial intelligence and machine learning techniques in precision oncology breakdown → 2025 ·npj Digital Medicine ·Elena Fountzilas, Tillman Pearce, Mehmet A. Baysal, Abhijit Chakraborty, Apostolia M. Tsimberidou	52
2	Preliminary evaluation of the safety and feasibility of toll-like receptor ligand CB101 combined with hypofractionated radiation therapy in canine head and neck cancer: a pilot study 2025 ·PubMed ·(unknown), (unknown), (unknown), Xiaowei Xu, John N. Lukens, Tillman Pearce, Michael Ehrhardt, Alain H. Rook, Amy C. Durham, Amit Maity, (unknown)	0
3	Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors 2023 ·British Journal of Cancer ·Apostolia M. Tsimberidou, Claire F. Verschraegen, Robert Wesolowski, Chi‐Sheng Shia, (unknown), Tillman Pearce	5
4	First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors 2023 ·JCO Precision Oncology ·Apostolia M. Tsimberidou, Henry Hiep Vo, Jennifer Beck, Chi‐Sheng Shia, (unknown), Tillman Pearce	9
5	Use of glycoproteome profiles to detect advanced adenomas and colorectal cancer. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), Ankita Shah, (unknown), Gege Xu, Klaus Lindpaintner, (unknown), Tillman Pearce, Daniël W. Hommes	1
6	A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors 2023 ·American Journal of Clinical Oncology ·Paula M. Fracasso, George A. Fisher, Sherry A. Goodner, Jan H. Beumer, Merrill J. Egorin, (unknown), (unknown), Gary J. Jones, Tillman Pearce, Branimir I. Šikić	6
7	Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models 2022 ·Molecular Cancer Therapeutics ·Didier Scherrer, (unknown), Luc Teyton, Tillman Pearce, Josianne Nitcheu, (unknown), (unknown), Hartmut J. Ehrlich	1
8	A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin 2022 ·Investigational New Drugs ·(unknown), (unknown), (unknown), Stephen V. Liu, Saad A. Khan, A. Dimitrios Colevas, Tillman Pearce, Danny Rischin	11
9	First-in-human study of OBI-999: A globo H-targeting antibody-drug conjugate in patients with advanced solid tumors. 2022 ·Journal of Clinical Oncology ·Apostolia M. Tsimberidou, (unknown), Tillman Pearce	1
10	A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). 2016 ·Journal of Clinical Oncology ·Danny Rischin, Michael Boyer, Christina Brzezniak, A. Dimitrios Colevas, Robert C. Doebele, Jill Gilbert, Barbara J. Gitlitz, Saad A. Khan, Ranee Mehra, Tanguy Y. Seiwert, Stew Kroll, Tillman Pearce, Stephen V. Liu	3
11	Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI. 2016 ·Journal of Clinical Oncology ·Stephen V. Liu, Charu Aggarwal, Christina Brzezniak, Robert C. Doebele, David E. Gerber, Barbara J. Gitlitz, Leora Horn, Benjamin Solomon, (unknown), Liza C. Villaruz, Howard West, Stew Kroll, Tillman Pearce, D. Ross Camidge	10
12	Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021 2016 ·Annals of Oncology ·William D. Tap, Zsolt Pápai, Brian A. Van Tine, Steven Attia, Kristen N. Ganjoo, Robin L. Jones, Scott M. Schuetze, Damon R. Reed, Sant P. Chawla, Richard F. Riedel, Anders Krarup‐Hansen, Antoîne Italiano, Peter Hohenberger, Giovanni Grignani, Lee D. Cranmer, Thierry Alcindor, Antonio López–Pousa, Tillman Pearce, (unknown), Patrick Schöffski	14
13	Randomized, Double-Blind, Placebo-Controlled Trial of Evofosfamide (TH-302) in Combination with Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer 2015 ·Annals of Oncology ·(unknown), Chandra P. Belani, Silvia Novello, Joachim von Pawel, Tibor Csőszi, Sergey Orlov, Stewart Kroll, Tillman Pearce	2
14	Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study 2009 ·Inflammatory Bowel Diseases ·Walter Reinisch, (unknown), László Bene, L Simón, I Rácz, Seymour Katz, I Altorjay, Brian G. Feagan, Dennis Riff, Çharles N. Bernstein, Daniël W. Hommes, Paul Rutgeerts, Antoine Cortot, (unknown), (unknown), Tillman Pearce, Bruce E. Sands	160
15	Alternative clinical end points in rectal cancer—are we getting closer? 2006 ·Annals of Oncology ·Rob Glynne‐Jones, S. Mawdsley, Tillman Pearce, Marc Buyse	75
16	Elitek™–rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002 2003 ·Leukemia ·Patrick M. Navolanic, C-H Pui, Richard A. Larson, Michael R. Bishop, Tillman Pearce, Mitchell S. Cairo, SJ Goldman, (unknown), Carl Shanholtz, John P. Leonard, James A. McCubrey	69
17	Pharmacokinetics (PK) and pharmacodynamics (PD) of SDZ PSC 833, a novel multidrug resistance reversing agent, in phase 1 trials with chemotherapeutic agents 1997 ·European Journal of Cancer ·(unknown), Paula M. Fracasso, (unknown), Pieter Sonneveld, (unknown), Giuseppe Giaccone, Werner Niederberger, Harold T. Smith, Tillman Pearce, Branimir I. Šikić	1
18	Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma 1996 ·Investigational New Drugs ·Jinee Rizzo, Alexandra M. Levine, Geoffrey R. Weiss, Tillman Pearce, Maura A. Kraynak, (unknown), Susan Smith, Daniel D. Von Hoff, (unknown)	12
19	Uniform detection of HIV-1 in alveolar macrophages of pediatric but not adult AIDS patients 1993 ·Journal of Leukocyte Biology ·Tillman Pearce, Maja Nowakowski, Edward Eden, (unknown), Phillip Steiner, (unknown), Mary Jane Potash, David J. Volsky	14
20	Virus-cell membrane fusion does not predict efficient infection of alveolar macrophages by human immunodeficiency virus type 1 (HIV-1) 1992 ·Virology ·Mary Jane Potash, Michael Zeira, (unknown), Tillman Pearce, Edward Eden, Howard E. Gendelman, David J. Volsky	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact